Genmab Reports Nine-Month 2026 Financial Results
Genmab released its interim report for the nine months ended September 30, 2026. The report highlights approval in Europe of TEPKINLY plus R(2) for second-line follicular lymphoma.
Story updates
04:02:31 PM UTC
SquawkNews
GENMAB: REVENUE WAS $3,238 MLN FOR FIRST NINE MONTHS OF 2026 COMPARED TO $2,662 MLN FOR FIRST NINE M